10-Q: Bioventus Inc. Reports Q1 2025 Results: Revenue Declines Amid Business Divestiture

Bioventus Inc.'s Q1 2025 net sales decreased by 4.3% year-over-year, primarily due to the divestiture of its Advanced Rehabilitation Business.

Summary

• Bioventus Inc. reported a net sales decrease of 4.3% to $123.9 million for the quarter ended March 29, 2025, compared to $129.5 million in the same period last year.
• The decline is primarily attributed to the divestiture of the Advanced Rehabilitation Business, which closed on December 31, 2024.
• The company's net loss was $3.3 million, compared to a net loss of $6.4 million in the prior year.
• Adjusted EBITDA was $19.2 million, down from $22.6 million in the first quarter of 2024.
• U.S. net sales decreased by 3.3%, while international net sales decreased by 12.0%.
• The company used proceeds from the Advanced Rehabilitation Business sale to pay down $20.0 million in long-term debt.
• Bioventus is pursuing potential earn-out payments of up to $20.0 million based on the performance of the divested business in 2025 and 2026.
• The company believes it has sufficient liquidity to continue operations for the next twelve months and repay the $10.0 million due October 29, 2025.
• The company is involved in ongoing shareholder derivative litigation, with settlement discussions underway.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company experienced a decrease in revenue and Adjusted EBITDA, it also reduced its net loss and paid down debt. The ongoing litigation and market risks contribute to a mixed outlook.

Positives

• Net loss decreased from $6.4 million to $3.3 million year-over-year.
• The company used proceeds from the Advanced Rehabilitation Business sale to pay down $20.0 million in long-term debt.
• The company is in compliance with financial covenants under its Amended 2019 Credit Agreement.
• The company believes it has sufficient liquidity to continue operations for the next twelve months and repay the $10.0 million due October 29, 2025.

Negatives

• Net sales decreased by 4.3% to $123.9 million due to the divestiture of the Advanced Rehabilitation Business.
• Adjusted EBITDA decreased to $19.2 million from $22.6 million year-over-year.
• U.S. net sales decreased by 3.3%, while international net sales decreased by 12.0%.

Risks

• The company's future performance is subject to various risks outlined in its 2024 Form 10-K, including economic, political, and regulatory risks related to international sales, manufacturing, and operations.
• The company is involved in ongoing shareholder derivative litigation, the outcome of which is uncertain.
• Failure to achieve and maintain adequate levels of coverage and/or reimbursement for our products or future products, the procedures using our products, such as our hyaluronic acid (HA) viscosupplements, or future products we may seek to commercialize.

Future Outlook

The company believes it has sufficient liquidity to continue operations for the next twelve months and repay the $10.0 million due October 29, 2025. The company anticipates that to the extent that it requires capital, it will obtain funding through additional equity financings or the incurrence of other indebtedness or a combination of these potential sources of capital.

Industry Context

The medical device industry is competitive and subject to extensive regulation. Bioventus competes with other companies, some of which have longer operating histories, more established products, or greater resources. The company's performance is also affected by factors such as reimbursement policies, technological advancements, and economic conditions.

Comparison to Industry Standards

• It is difficult to provide a direct comparison to industry standards without specific competitor data.
• However, medical device companies such as Stryker, Zimmer Biomet, and Medtronic are often used as benchmarks for performance.
• These companies typically have higher revenue and market capitalization than Bioventus, but Bioventus focuses on specific niches within orthopedics and pain management.
• The divestiture of the Advanced Rehabilitation Business may allow Bioventus to focus on its core areas and improve profitability.

Legal Proceedings

• The company is involved in ongoing shareholder derivative litigation, with settlement discussions underway.
• The parties settled without any admission of liability or wrongdoing by any party.
• The settlement amount of $15.3 million, together with interest earned thereon, has been paid by the defendants and/or the defendants insurers.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and Adjusted EBITDA, but reassured by the reduction in net loss and debt.
• Employees may be affected by the divestiture of the Advanced Rehabilitation Business.
• Customers may experience changes in product availability and support due to the divestiture.

Next Steps

• The company expects a post-closing adjustment for net working capital related to the Advanced Rehabilitation Business sale to be settled in the second quarter of 2025.
• The company may receive up to $20.0 million in earn-out payments based on the performance of the divested business in 2025 and 2026.
• The parties in the shareholder derivative litigation will file another status update by June 23, 2025.
• The company will need to repay the $10.0 million outstanding on its Revolver by October 29, 2025.

Key Dates

Keywords

Bioventus, financial results, medical devices, net sales, Adjusted EBITDA, Advanced Rehabilitation Business, divestiture, litigation, orthopedics, pain management